StockNews.AI
IRIX
StockNews.AI
13 days

Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

1. Iridex Corporation will announce 2024 financial results on March 27, 2025. 2. A conference call will be held post-announcement for investor insights. 3. Iridex specializes in laser technology for glaucoma and retinal conditions. 4. The company operates in over 100 countries through distributors. 5. Their MicroPulse® technology is crucial for eye condition treatments.

Earnings
+16.49%Current Return
VS
+2.07%S&P 500
$0.9703/13 05:07 PM EDTEvent Start
$1.1303/14 11:20 PM EDTLatest Updated
4 mins saved
Full Article

FAQ

Why Bullish?

Upcoming financial results often lead to increased investor interest and stock price movement. Strong quarterly results can reflect business growth, attracting more investment.

How important is it?

Investors closely watch earnings announcements for growth indicators. Given Iridex's role in the medical technology sector, positive results could drive stock performance significantly.

Why Short Term?

The imminent earnings announcement is likely to influence stock prices directly. Historical cases show stocks often react within days before and after earnings releases.

Related Companies

ALRMMDCOTMO
March 13, 2025 17:00 ET  | Source: IRIDEX Corporation MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 5685253. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com. About Iridex Corporation Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com. MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved. Investor Relations Contact:Philip TaylorGilmartin Groupinvestors@iridex.com

Related News